MBNP
MCID: MMB011
MIFTS: 50

Membranous Nephropathy (MBNP)

Categories: Nephrological diseases, Rare diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 57 12 20 29 15
Membranous Glomerulonephritis 12 20 15 17 70
Membranous Nephropathy, Susceptibility to 57 13
Idiopathic Membranous Glomerulonephritis 58 70
Idiopathic Membranous Nephropathy 20 54
Glomerulonephritis, Membranous 20 44
Primary Membranous Glomerulonephritis 58
Extramembranous Glomerulonephritis 20
Primary Membranous Nephropathy 58
Nephropathy Membranous 54
Membranous Gn 20
Mbnp 57
Mgn 20

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:10976
OMIM® 57 614692
MeSH 44 D015433
NCIt 50 C34645
SNOMED-CT 67 197710000
ICD10 32 N03.2
ICD10 via Orphanet 33 N04.2
UMLS via Orphanet 71 C0086445
Orphanet 58 ORPHA97560
UMLS 70 C0017665 C0086445

Summaries for Membranous Nephropathy

OMIM® : 57 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692) (Updated 05-Apr-2021)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to proteinuria, chronic benign and glomerular disease. An important gene associated with Membranous Nephropathy is MBNP (?Membranous Nephropathy, Susceptibility To), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Nephrin/Neph1 signaling in the kidney podocyte. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and neutrophil, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

GARD : 20 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause of membranous nephropathy is not known. Some cases are associated with other conditions ( lupus ), infections ( hepatitis B and C), cancer or as a side effect of certain medications. The goal of treatment is to reduce symptoms and slow the progression of the disease.

Wikipedia : 73 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Fetomaternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 589)
# Related Disease Score Top Affiliating Genes
1 proteinuria, chronic benign 31.6 NPHS2 NPHS1 LRP2 CD79A CD2AP ALB
2 glomerular disease 31.4 CD79A CD2AP ALB ACE
3 interstitial nephritis 31.2 TINAG ALB ACE
4 idiopathic nephrotic syndrome 31.2 NPHS2 ALB ACE
5 microvascular complications of diabetes 3 31.1 NPHS1 ALB ACE
6 goodpasture syndrome 31.0 PLA2R1 NPHS1 ALB
7 glomerulonephritis 30.9 NPHS2 NPHS1 LRPAP1 LRP2 CD79A C3
8 membranoproliferative glomerulonephritis 30.9 NPHS1 CD79A C3 ALB
9 syphilis 30.8 CD79A ALB ACE
10 end stage renal disease 30.8 TRPC6 NPHS2 NPHS1 CD2AP C3 ALB
11 chronic kidney disease 30.7 PECAM1 NPHS2 NPHS1 ALB ACE
12 iga glomerulonephritis 30.7 NPHS2 NPHS1 CD79A CD2AP C3 ALB
13 rapidly progressive glomerulonephritis 30.7 PLA2R1 NPHS1 C3 ALB
14 purpura 30.7 CD79A C3 ACE
15 nephrotic syndrome 30.6 VTN TRPC6 PODXL NPHS2 NPHS1 LRP2
16 acute kidney tubular necrosis 30.5 LRP2 ALB ACE
17 nephrotic syndrome, type 1 30.5 NPHS2 NPHS1 CD2AP
18 portal hypertension 30.4 PECAM1 ALB ACE
19 guillain-barre syndrome 30.4 HLA-DQA1 CD79A ALB
20 arteriolosclerosis 30.4 CD79A C3 ALB
21 kimura disease 30.3 THSD7A PLA2R1
22 focal segmental glomerulosclerosis 30.3 VTN TRPC6 PODXL NPHS2 NPHS1 MME
23 obstructive nephropathy 30.2 TINAG ALB ACE
24 nail-patella syndrome 30.2 NPHS2 NPHS1 CD2AP
25 nephrosclerosis 30.2 NPHS2 NPHS1 ACE
26 angioedema 30.2 MME C3 ACE
27 congenital syphilis 30.2 NPHS2 NPHS1 CD79A
28 cerebral lymphoma 30.1 MME LRP2 CD79A
29 pyuria 30.0 C3 ALB
30 alport syndrome 29.8 TRPC6 NPHS2 NPHS1 CD2AP ALB ACE
31 kidney disease 29.7 TRPC6 PECAM1 NPHS2 NPHS1 LRP2 CD79A
32 lipoid nephrosis 29.2 TRPC6 PODXL PLA2R1 NPHS2 NPHS1 CD79A
33 congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization 11.3
34 autoimmune disease 10.7
35 hepatitis b 10.7
36 crescentic glomerulonephritis 10.6
37 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
38 hepatitis 10.5
39 vasculitis 10.5
40 graft-versus-host disease 10.5
41 igg4-related disease 10.5
42 lupus erythematosus 10.4
43 microvascular complications of diabetes 4 10.4
44 microvascular complications of diabetes 6 10.4
45 microvascular complications of diabetes 7 10.4
46 sarcoidosis 1 10.4
47 chronic graft versus host disease 10.4
48 sarcomatoid squamous cell skin carcinoma 10.4 PECAM1 MME
49 hypereosinophilic syndrome 10.4
50 pulmonary artery leiomyosarcoma 10.4 PECAM1 MME

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM®:

614692 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB C3 CD79A HLA-DQA1 LRP2 PLA2G1B

MGI Mouse Phenotypes related to Membranous Nephropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 ACE ALB C3 CD2AP CD79A LRP2
2 renal/urinary system MP:0005367 9.32 ACE ALB C3 CD2AP CD79A LRP2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Mycophenolic acid Approved Phase 4 24280-93-1 446541
11
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
12
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Adrenocorticotropic Hormone Phase 4
15 Melanocyte-Stimulating Hormones Phase 4
16 beta-Endorphin Phase 4
17 Tripterygium Phase 4
18 Antirheumatic Agents Phase 4
19 Immunologic Factors Phase 4
20 Cyclosporins Phase 4
21 Immunosuppressive Agents Phase 4
22 Dermatologic Agents Phase 4
23 Calcineurin Inhibitors Phase 4
24 Anti-Infective Agents Phase 4
25 Antifungal Agents Phase 4
26 Hormone Antagonists Phase 4
27 Hormones Phase 4
28 Methylprednisolone Acetate Phase 4
29 glucocorticoids Phase 4
30 Antineoplastic Agents, Hormonal Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Antibiotics, Antitubercular Phase 4
33 Anti-Bacterial Agents Phase 4
34 Antitubercular Agents Phase 4
35 Giapreza Phase 4
36 Angiotensinogen Phase 4
37 Angiotensin Receptor Antagonists Phase 4
38 Antihypertensive Agents Phase 4
39 Angiotensin II Type 1 Receptor Blockers Phase 4
40
Deflazacort Approved, Investigational Phase 3 14484-47-0
41
Chlorambucil Approved Phase 3 305-03-3 2708
42
rituximab Approved Phase 3 174722-31-7 10201696
43
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
44
Azathioprine Approved Phase 3 446-86-6 2265
45
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
46
Promethazine Approved, Investigational Phase 3 60-87-7 4927
47
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
48
Acetaminophen Approved Phase 3 103-90-2 1983
49
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
50 Vasoconstrictor Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 66)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
2 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
3 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
4 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
5 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Completed NCT03025828 Phase 4 ACTHar
6 Immunoadsorption in Anti-glomerular Basement Membrane Glomerulonephritis; a Pilot Study Recruiting NCT02765789 Phase 4
7 Multitarget Therapy for Idiopathic Membranous Nephropathy Not yet recruiting NCT04424862 Phase 4 Prednisone, ciclosporin and mycophenolate mofetil;Ponticelli Regimen
8 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
9 Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) Unknown status NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
10 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
11 Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
12 Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
13 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
14 "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)" Completed NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
15 Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
16 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
17 European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) Completed NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
18 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
19 A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT04743739 Phase 3 Rituximab;cyclosporine
20 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Active, not recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
21 Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort Not yet recruiting NCT04745728 Phase 3 Prednisone;Cyclophosphamide;Rituximab
22 A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy Not yet recruiting NCT04629248 Phase 3 Obinutuzumab;Tacrolimus;Methylprednisolone;Acetaminophen;Diphenhydramine
23 Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
24 Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study Completed NCT00694863 Phase 2 tetracosactide hexacetaat
25 A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
26 Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
27 A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN) Completed NCT03285711 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanraplenib placebo
28 BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
29 A Randomized, Treatment Open-label, Dose-blinded Parallel Group, Three Arm, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Recruiting NCT04154787 Phase 2 LNP023;Rituximab
30 An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 4 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy Recruiting NCT04456816 Phase 2 100 mg AP1189;Placebo
31 Personalized Medicine for Membranous Nephropathy Recruiting NCT03804359 Phase 2 Rituximab
32 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
33 Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI) Recruiting NCT03949855 Phase 2 Belimumab;Placebo for Belimumab;Rituximab
34 A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) Recruiting NCT04145440 Phase 1, Phase 2 MOR202
35 A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) Recruiting NCT04733040 Phase 2 MOR202
36 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Recruiting NCT02682407 Phase 2
37 A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) Active, not recruiting NCT03453619 Phase 2 APL-2
38 A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy Not yet recruiting NCT04652570 Phase 1, Phase 2 VB119
39 BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
40 A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT00805753 Phase 1 ACTH
41 A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome Recruiting NCT04278729 Phase 1 Apixaban 5 MG
42 A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
43 Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study Unknown status NCT01845688 Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule
44 Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies Unknown status NCT01799460 The Comprehensive Treatment Regimen of Traditional Chinese Medicine;The immunosuppressive agents
45 A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation) Unknown status NCT02610595 Jianpixiaozhong particles and Wuse Dietotherapy
46 The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. Unknown status NCT03466801 Prednisone;MP and CTX
47 Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA Unknown status NCT02199145
48 Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation Unknown status NCT01897961
49 Efficacy and Safety of Rituximab in Patients With Refractory Primary Membranous Nephropathy Completed NCT03880643
50 Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy Completed NCT00983034 lansoprazole, amoxicillin, clarithromycin

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

40
Kidney, Endothelial, Neutrophil, Bone Marrow, Skin, Thyroid, B Cells

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 5175)
# Title Authors PMID Year
1
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. 61 57
25394321 2014
2
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. 57 61
21323563 2011
3
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. 57 61
21323541 2011
4
Familial membranous nephropathy: an X-linked genetic susceptibility? 61 57
18075275 2008
5
Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. 57 61
12087141 2002
6
Familial membranous nephropathy. 61 57
6439290 1984
7
Membranous glomerulopathy: the evolving story. 61 54
20110811 2010
8
Association between genetic polymorphisms of the NPHS1 gene and membranous glomerulonephritis in the Taiwanese population. 61 54
20138859 2010
9
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. 61 54
20185638 2010
10
Autoimmune kidney diseases. 61 54
19906361 2010
11
Phosphorylation status of nephrin in human membranous nephropathy. 61 54
19882202 2010
12
[The involvement of neprilysin in the pathogenesis of glomerulopathies]. 61 54
19827739 2009
13
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 54 61
19169768 2009
14
[Immunosuppressive treatment of idiopathic membranous glomerulonephritis with nephrotic syndrome]. 54 61
20088170 2009
15
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 61 54
19820874 2009
16
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 54 61
19562271 2009
17
B cells and tertiary lymphoid organs in renal inflammation. 61 54
18094677 2008
18
[Advances in primary glomerular disease in 2007]. 54 61
18847426 2008
19
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 61 54
18925530 2008
20
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. 61 54
18272039 2008
21
Expression of nestin in the podocytes of normal and diseased human kidneys. 54 61
17255215 2007
22
Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. 54 61
17200187 2007
23
Role of podocyte slit diaphragm as a filtration barrier. 61 54
16889564 2006
24
Glomerular clusterin is associated with PKC-alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. 61 54
16775601 2006
25
Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study. 54 61
16528253 2006
26
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 54 61
16285662 2005
27
Mechanisms of immune-deposit formation and the mediation of immune renal injury. 61 54
16189625 2005
28
Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. 61 54
15882266 2005
29
IgA deficiency and membranous glomerulonephritis presenting as nephrotic syndrome. 54 61
15711951 2005
30
Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. 61 54
15385633 2004
31
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. 61 54
15464186 2004
32
Glomerular expression of biglycan and decorin and urinary levels of decorin in primary glomerular disease. 61 54
14964452 2004
33
Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. 61 54
14633129 2003
34
[Pathogenesis of immune glomerulonephritis]. 54 61
15008213 2003
35
Pathological demography of native patients in a nephrology center in China. 54 61
14527370 2003
36
Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry. 61 54
12830459 2003
37
Urinary excretion of complement C3d in patients with renal diseases. 54 61
12795640 2003
38
Glomerular expression of connective tissue growth factor mRNA in various renal diseases. 61 54
15012739 2003
39
IgA deficiency with membranous glomerulonephritis: a case report and review. 61 54
12649548 2003
40
Depletion of clusterin in renal diseases causing nephrotic syndrome. 54 61
12427144 2002
41
Differential expression of nephrin in acquired human proteinuric diseases. 61 54
12407641 2002
42
Frequency of renal pathology in Spain 1994-1999. 61 54
12198210 2002
43
Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. 61 54
11912254 2002
44
Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up-regulation in IgA nephropathy. 61 54
11527413 2001
45
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. 61 54
11337370 2001
46
Expression of nephrin in pediatric kidney diseases. 54 61
11158218 2001
47
Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. 54 61
11135066 2001
48
No complement receptor 1 stumps on podocytes in human glomerulopathies. 61 54
11135068 2001
49
Vascular hyperpermeability in nephrotic edema. 61 54
10867533 2000
50
Changing incidence of glomerular diseases in adults. 54 61
10793022 2000

Variations for Membranous Nephropathy

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

Pathways related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.04 VTN TRPC6 PODXL NPHS2 NPHS1 MME
2 10.67 TRPC6 NPHS2 NPHS1 CD2AP

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 VTN TINAG THSD7A PLA2R1 PLA2G1B LRPAP1
2 extracellular space GO:0005615 10.03 VTN TINAG PODXL PLA2G1B PECAM1 C3
3 plasma membrane GO:0005886 10.03 TRPC6 THSD7A PODXL PLA2R1 PECAM1 NPHS2
4 integral component of plasma membrane GO:0005887 9.92 TRPC6 PODXL PLA2R1 PECAM1 NPHS2 NPHS1
5 cell surface GO:0009986 9.85 PLA2R1 PLA2G1B MME LRPAP1 C3
6 extracellular exosome GO:0070062 9.7 VTN PODXL PECAM1 NPHS2 NPHS1 MME
7 cell-cell junction GO:0005911 9.67 PECAM1 NPHS2 NPHS1 CD2AP
8 membrane raft GO:0045121 9.65 PODXL PECAM1 NPHS2 MME CD79A
9 endosome lumen GO:0031904 9.48 LRPAP1 LRP2
10 slit diaphragm GO:0036057 8.92 TRPC6 PODXL NPHS2 NPHS1

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.43 PLA2R1 MME
2 amyloid-beta metabolic process GO:0050435 9.4 MME ACE
3 angiotensin maturation GO:0002003 9.37 MME ACE
4 neutrophil mediated immunity GO:0002446 9.32 PLA2G1B ACE
5 glomerular visceral epithelial cell development GO:0072015 9.26 PODXL NPHS1
6 positive regulation of glomerular visceral epithelial cell apoptotic process GO:1904635 9.16 PLA2R1 PLA2G1B
7 regulation of receptor-mediated endocytosis GO:0048259 8.96 LRPAP1 CD2AP
8 amyloid-beta clearance GO:0097242 8.8 MME LRP2 C3

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 exopeptidase activity GO:0008238 8.62 MME ACE

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....